Castle Biosciences Inc (CSTL)
Computer Software and Services • Information Technology
May 06, 2026 Castle Biosciences Inc. Reports 2026 Q1 Financial Results: Navigating Challenges and Opportunities Castle Biosciences' Q1 2026 report reveals a revenue drop of 4.9% but significant growth in non-dermatologic testing. Despite challenges in reimbursement, the company focuses on innovation and operational efficiency for future growth.
March 13, 2026 Castle Biosciences Inc. Press Release Highlights Groundbreaking Study on DecisionDx®-Melanoma Castle Biosciences has unveiled groundbreaking results from a study on the DecisionDx-Melanoma test, which effectively identifies low- and high-risk melanoma patients. The study highlights significant improvements in risk stratification, potentially reducing unnecessary surgeries while enhancing patient outcomes.
February 26, 2026 Castle Biosciences Inc. Reports 2025 Annual Results: A Year of Growth Amid Challenges Castle Biosciences Inc. reported a 3.7% revenue increase in 2025, totaling $344.2 million, driven by non-dermatologic tests. Despite this growth, the company faced significant challenges, including operating losses and reimbursement issues. Strategic product launches and acquisitions signal a commitment to innovation amid a complex healthcare landscape.
November 03, 2025 Castle Biosciences Inc. Reports Q3 2025 Results: Navigating Challenges in a Competitive Landscape Castle Biosciences Inc. reported Q3 2025 revenues of $83 million, down 3.2% due to Medicare coverage losses affecting dermatologic tests. However, non-dermatologic tests like TissueCypher saw growth, and strategic acquisitions position the company for future success.
August 04, 2025 Castle Biosciences Inc. Reports Mixed Q2 2025 Results Amidst Challenges Castle Biosciences Inc. faced challenges in Q2 2025 with a slight revenue decline due to loss of Medicare coverage for key tests. Despite this, the company showed resilience with growth in non-dermatologic segments and maintains strong financial health.
May 05, 2025 Castle Biosciences Inc. Reports Q1 2025 Financial Results: Growth Amid Challenges Castle Biosciences Inc. reported a 20.6% increase in Q1 2025 revenues, reaching $88 million, driven by higher test volumes. However, the company faced operational losses and reimbursement challenges that could affect future profitability.
March 07, 2025 Castle Biosciences Showcases New Data at 2025 AAD Annual Meeting Castle Biosciences presented new findings at the 2025 AAD Annual Meeting, emphasizing the clinical value of its dermatology tests, DecisionDx-Melanoma and DecisionDx-SCC. The studies demonstrated significant advancements in patient care and risk stratification for skin cancer management.
February 27, 2025 Castle Biosciences Reports Robust Growth in 2024 Financial Results Castle Biosciences experienced significant growth in 2024, with revenues increasing by 51% to $332.1 million. The company also reported improved test volumes and operational efficiency, positioning itself for further success in 2025 with projected revenues of $280 to $295 million.
February 27, 2025 Castle Biosciences Inc. Reports Strong Growth in 2024 Annual Report Castle Biosciences Inc. announced a 51% revenue increase in its 2024 annual report, driven by successful diagnostic products. The company also achieved positive net income and cash flow, positioning itself for future growth despite challenges like reimbursement uncertainties.
February 25, 2025 Castle Biosciences Inc. Announces Participation in Key Investor Conferences Castle Biosciences, a leader in health diagnostics, will present at two key investor conferences in March 2025. The events will highlight the company's innovative diagnostic tests and future strategic direction, emphasizing its commitment to patient care and stakeholder engagement.
February 12, 2025 Castle Biosciences Showcases Innovative Dermatologic Tests at the 22nd Annual Winter Clinical Dermatology Conference Castle Biosciences will showcase its groundbreaking dermatologic tests at the 22nd Annual Winter Clinical Dermatology Conference in Hawaii. The company's presentations will highlight the clinical value of their gene expression profile tests, aimed at enhancing patient care for skin cancer treatment decisions.
February 06, 2025 Castle Biosciences Set to Announce Fourth Quarter and Full-Year 2024 Financial Results Castle Biosciences is set to announce its Q4 and full-year 2024 financial results on February 27, 2025. Investors can join a conference call for detailed insights into the company's performance and future plans.
February 05, 2025 SWOT Analysis of Castle Biosciences Inc in 2025 This SWOT analysis of Castle Biosciences Inc in 2025 reveals its strong portfolio in molecular diagnostics and opportunities for growth, alongside challenges like financial reliance and regulatory risks. Understanding these factors is essential for stakeholders to gauge the company's strategic position.
November 04, 2024 Castle Biosciences Inc. Reports Strong Q3 2024 Financial Results Castle Biosciences Inc. demonstrated significant progress in Q3 2024, reporting a net income of $2.26 million and total revenue of $85.78 million. The company’s strategic expansions and product innovations have contributed to its strong performance, despite facing challenges with Medicare coverage.
August 05, 2024 Castle Biosciences Inc. Reports Impressive Growth in Q2 2024 Financials Castle Biosciences Inc. reported impressive financial growth in Q2 2024, with revenues rising 73.5% to $87 million and a net income of $8.92 million. The company also strengthened its balance sheet and expanded its commercial efforts, positioning itself for continued success in the molecular diagnostics market.
May 02, 2024 Castle Biosciences Inc. Reports Impressive Q1 2024 Results Despite Ongoing Losses Castle Biosciences Inc. posted a remarkable 73.6% revenue increase in Q1 2024, driven by strong sales of diagnostic tests. Despite a net loss, the company's improved operational efficiency and market expansion strategies indicate a positive outlook for future profitability.